22nd November
Current Perspectives in Haematological Malignancies
Bristol

DoubleTree by Hilton, Bristol City Centre, Redcliffe Way, Bristol, BS1 6NJ

Chairs: Dr Stephen Robinson (Bristol) and Dr Andrew McMillan (Nottingham)

Topics:
Continuous therapy in myeloma – the future
Myeloma – upfront and RRMM
CLL – heading for a cure?
High risk and resistant CML: new diagnostic tools and treatment approaches
Myeloproliferative neoplasms – current thinking
Workshop: AML

Debates:
ECHELON 1 : Brentuximab should be used first line in advanced Hodgkin lymphoma
GALLIUM : Obinutuzumab, not rituximab, should be used first line for patients with symptomatic follicular lymphoma

Confirmed Speakers:

  • Dr Priyanka Mehta (University Hospital Bristol)
  • Professor Chris Fegan (Cardiff University)
  • Dr Sally Moore (Royal United Hospitals Bath)
  • Dr Graham Collins (Oxford University Hospitals)
  • Dr Stephen Robinson (University Hospitals Bristol)
  • Dr Andrew McMillan (Nottingham City Hospital)
  • Dr Wendy Osborne (Freeman Hospital, Newcastle)
  • Dr Steve Knapper (University Hospital, Wales)
  • Professor Claire Harrison (Guy’s and St Thomas’ Hospital, London)
  • Dr Hugues de Lavallade (King’s College Hospital, London)

Registration Fees:

(inclusive of VAT @ 20%)

Consultants

Trainees / Nurses*

Standard Fee (until 7th November)

£72

£60

Late Fee (from 8th November)

£108

£108

 

* 20 free places available for Trainees & Nurses (allocated on a first-come, first-served basis – please email alex@hartleytaylor.co.uk to check availability)

Enquiries:

Registration questions: alex@hartleytaylor.co.uk
Sponsorship opportunities: julie@hartleytaylor.co.uk

Hartley Taylor Medical Communications Ltd
Caledonian House | Tatton Street
Knutsford | Cheshire | WA16 6AG
Tel: ++44 (0)1565 621967